Intend Research, LLC
Norman, Oklahoma, 73069, United States
NCT Number: NCT03922945
This study is being conducted to assess weight loss efficacy, as determined by changes in body mass index (BMI), and safety of VI-0521 (Qsymia®) or placebo, taken for 56 weeks accompanied by a lifestyle modification program in obese adolescents age 12-16 years.
Looking for future studies?
Notify Me12 year–16 year
All sexes
Interventional
Phase 4
Norman, Oklahoma, 73069, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Phentermine/Topiramate
Other names: Qsymia, Phentermine and topiramate
Inactive drug
The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
Time frame: Baseline to Week 56
Mean % change in BMI from Baseline to Week 56
Time frame: Baseline to Week 56
Time frame: Baseline to Week 56
Time frame: Baseline to Week 56
Time frame: Baseline, Week 56
Change in waist circumference from Baseline to Week 56
Time frame: Baseline, Week 56
Mean changes in glycemic parameters [Whole Body Insulin Sensitivity Index (WBISI) (Matsuda)] from baseline to Week 56. The Oral Glucose Tolerance Test (OGTT) were performed at Baseline and Week 56 using 75 g oral glucose load; blood samples were obtained at baseline and at 2 hours post glucose load for evaluation of both glucose and insulin levels. Insulin Sensitivity was measured by obtaining glucose and insulin levels in a fasting state and at 2 hours after administration of oral glucose load. Matsuda index = 10,000/SQRT [glucose concentration (mg/dL) (fasting)*insulin concentration (uIU/mL) (fasting)*glucose concentration (mg/dL) (2 hours after glucose load)*insulin concentration (uIU/mL) (2 hours after glucose load)], with higher numbers indicating better insulin sensitivity.
Time frame: Baseline, Week 56
Change in fasting insulin from Baseline to Week 56
Time frame: Baseline, Week 56
Time frame: Baseline, Week 56
Time frame: Baseline, Week 56
Time frame: Baseline, Week 56
VIVUS LLC
Industry
A Phase IV, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Determine the Safety and Efficacy of VI-0521 in Obese Adolescents
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05247918
Adolescent Obesity, Behavior
Gothenburg, Sweden
View Trial DetailsNCT03620773
Adolescent Obesity, Bariatric Surgery Candidate
Aurora, Colorado, United States
View Trial DetailsNCT03843424
Adolescent Obesity, Body Weight
Alton, Illinois, United States
View Trial DetailsNCT05764291
Adolescent Behavior, Adolescent Obesity
Seri Kembangan, Selangor, Malaysia
View Trial Details